Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Immunology and Allergy ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.Arthritis Rheum. 2010; 62: 1583-1591
- Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort.Am J Respir Crit Care Med. 2019; 200: 1258-1266
- Interstitial lung disease in polymyositis and dermatomyositis.Arthritis Rheum. 2002; 47: 614-622
- Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes.Am J Respir Crit Care Med. 2007; 175: 705-711
- Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).Respir Med. 2013; 107: 1247-1252
- Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease.Eur Respir J. 2016; 47: 588-596
- Prognostic factors for myositis-associated interstitial lung disease.PLoS One. 2014; 9: e98824
- Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.Ann Rheum Dis. 2019; 78: 122-130
- The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements.The Lancet Rheumatology. 2020; 2: e71-e83
- Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline.Am J Respir Crit Care Med. 2022; 205: e18-e47
- 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis.Arthritis Rheumatol. 2021; 73: 1108-1123
- Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis.Arthritis Rheum. 1983; 26: 1269-1274
- Methotrexate and rheumatoid arthritis associated interstitial lung disease.Eur Respir J. 2020; 57: 2000337
- Can we finally exonerate methotrexate as a factor in causing or exacerbating fibrotic interstitial lung disease in patients with rheumatoid arthritis?.Clin Rheumatol. 2022; 41: 2925-2928
- Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis.Thorax. 1997; 52: 377-379
- Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis.BMJ Open. 2014; 4: e005615
- Rheumatoid arthritis treatment and the risk of severe interstitial lung disease.Scand J Rheumatol. 2007; 36: 172-178
- Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?.Drug Des Dev Ther. 2019; 13: 2111-2125
- Biological treatments and connective tissue disease associated interstitial lung disease.Curr Opin Pulm Med. 2011; 17: 362-367
- Rheumatoid arthritis-related interstitial lung disease (RA-ILD): a possible association between disease activity and prognosis.Clin Rheumatol. 2022; 41: 1741-1747
- Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study.Arthritis Rheumatol. 2019; 71: 1472-1482
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Respir Med. 2020; 8: 963-974
- Cyclophosphamide versus placebo in scleroderma lung disease.N Engl J Med. 2006; 354: 2655-2666
- Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.Lancet Respir Med. 2016; 4: 708-719
- Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.N Engl J Med. 2012; 366: 1968-1977
- Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis associated interstitial lung disease.Eur Respir J. 2021; 57: 2002533
- Usual interstitial pneumonia (UIP): a clinically significant pathologic diagnosis.Mod Pathol. 2022; 35: 580-588
- Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.N Engl J Med. 2014; 370: 2071-2082
- A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.N Engl J Med. 2014; 370: 2083-2092
- Nintedanib for systemic sclerosis-associated interstitial lung disease.N Engl J Med. 2019; 380: 2518-2528
- Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.Lancet Respir Med. 2023; 11: 87-96
- Nintedanib in progressive fibrosing interstitial lung diseases.N Engl J Med. 2019; 381: 1718-1727
- The pathogenesis of pulmonary fibrosis: a moving target.Eur Respir J. 2013; 41: 1207-1218
- Escape from the matrix: multiple mechanisms for fibroblast activation in pulmonary fibrosis.Proc Am Thorac Soc. 2008; 5: 311-315
- MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease.N Engl J Med. 2018; 379: 2209-2219
- Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers.Ann Rheum Dis. 2021; 80: 1530-1536
- A common MUC5B promoter polymorphism and pulmonary fibrosis.N Engl J Med. 2011; 364: 1503-1512
- Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations.Front Immunol. 2021; 12: 684699
- Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers.Am J Respir Crit Care Med. 2015; 191: 1403-1412
- British Rheumatoid Interstitial Lung N. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study.Rheumatology. 2014; 53: 1676-1682
- Prediction of pulmonary complications and long-term survival in systemic sclerosis.Arthritis Rheumatol. 2014; 66: 1625-1635
- Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis.PLoS One. 2016; 11: e0155381
- Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.Arthritis Rheumatol. 2020; 72: 465-476
- Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease.Am J Respir Crit Care Med. 2020; 201: 650-660
- The role of myositis-specific autoantibodies and the management of interstitial lung disease in idiopathic inflammatory myopathies: a systematic review.Semin Arthritis Rheum. 2022; 57: 152088
- Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease.PLoS One. 2014; 9: e98794
- Neutrophil extracellular traps kill bacteria.Science. 2004; 303: 1532-1535
- N-Formyl methionine peptide-mediated neutrophil activation in systemic sclerosis.Front Immunol. 2021; 12: 785275
- NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis.Sci Transl Med. 2013; 5: 178ra140
- Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies.JCI Insight. 2020; 5e134189
- Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones.PLoS One. 2012; 7: e32366
- Neutrophil extracellular traps promote differentiation and function of fibroblasts.J Pathol. 2014; 233: 294-307
- Neutrophil extracellular traps activate lung fibroblast to induce polymyositis-related interstitial lung diseases via TLR9-miR-7-Smad2 pathway.J Cell Mol Med. 2020; 24: 1658-1669
- Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2.Ann Rheum Dis. 2015; 74: 1417-1424
- A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice.Eur Respir J. 2012; 40: 1475-1482
- Association of Sputum Neutrophil Extracellular Trap Subsets With IgA Anti-Citrullinated Protein Antibodies in Subjects at Risk for Rheumatoid Arthritis.Arthritis Rheumatol. 2022; 74: 38-48
- Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.Chest. 2008; 133: 226-232
- Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study.Ann Rheum Dis. 2019; 78: 179-185
- Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial.Lancet (London, England). 2022; 400: 283-294
- Prospective Identification of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Cohort is Associated with the MUC5B Promoter Variant.Am J Respir Crit Care Med. 2022; 205: 473-476
- A risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease.Arthritis Rheumatol. 2022; 74: 1755-1765
- Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis.Eur Respir J. 2017; 49: 1602314
- Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years.Ann Rheum Dis. 2003; 62: 722-727
- Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis.Arthritis Rheumatol. 2015; 67: 2205-2212
- High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis.J Rheumatol. 2006; 33: 1789-1801
- Subclinical interstitial lung disease in patients with systemic sclerosis. A pilot study on the role of ultrasound.Reumatol Clínica. 2021; 17: 144-149
- Subclinical ILD is frequent and progresses across different connective tissue diseases.Eur Respir J. 2021; 58: OA2973
- Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.Respir Res. 2023; 24: 6
- Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis.Arthritis Rheum. 2006; 54: 1435-1439
- Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.Semin Arthritis Rheum. 2011; 41: 256-264
- Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease.Am J Respir Crit Care Med. 1997; 155: 1011-1020
- Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration adverse drug reaction reports.Arch Intern Med. 1992; 152: 1521-1524
- Sulphasalazine and lung toxicity.Eur Respir J. 2002; 19: 756-764
- Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows.J Clin Med. 2020; 9: 1082
- Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.Respir Med. 2016; 121: 117-122
- Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.Rheumatology. 2017; 56: 1348-1357
- Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis-associated interstitial lung disease.Respir Med. 2019; 154: 6-11
- Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease.Respir Med. 2019; 154: 6-11
- Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease.Pulm Pharmacol Ther. 2016; 36: 46-52
- Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of scleroderma lung study II.ACR Open Rheumatol. 2020; 2: 362-370
Article info
Publication history
Published online: March 03, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
